Technology Investment Summary

Disruptive Platform Technology
Linker Sciences combines high-resolution mass spectrometry, advanced laboratory automation, and AI-driven data analytics to improve small molecule drug discovery. The platform enables high-throughput identification and validation of bioactive compounds with improved speed, sensitivity, and reproducibility compared to conventional methods. Linker Sciences is developing proprietary workflows and system-level integration that combine established technologies in a novel, protected configuration.

Dual Strategy: Platform + Pipeline
Our disease-agnostic core enables application across diverse therapeutic areas, while retaining the ability to target high-value indications based on investor preference or market opportunity.

Massive Market Opportunity
Our platform addresses core inefficiencies in early-stage discovery including long timelines, high costs, and high attrition. By streamlining hit validation and lead selection, we increase R&D efficiency and enable productive collaborations with pharma and biotech partners.

Clear Technical Moat
Our proprietary experimental protocols and AI-based analytics form a defensible technical foundation. Early benchmarking indicates improved hit rates and validation accuracy compared to conventional screening workflows.

Early Execution and Momentum
We’ve designed a prototype discovery platform, onboarded advisors with pharma backgrounds, and have access to curated compound libraries and data pipelines.

Strategic Fit for Mission-Aligned Investors
Our platform offers early investors a scalable entry point into therapeutics R&D, with options for pipeline co-development or strategic exits via platform licensing.

Capital Raising Status
We are raising pre-seed capital to support platform validation, expand team capacity, and initiate pilot discovery projects. We are actively speaking with angels, early-stage biotech investors, and domain-focused VC funds.

Let’s Talk
Reach us directly at info@LinkerSciences.com to discuss the opportunity, review our pitch deck, or arrange a call.